Logo

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Share this

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Shots:

  • The two OLE P-III 1489 and 1490 studies assessing Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) vs dolutegravir-containing triple for the treatment of HIV-1 in treatment naïve adults
  • The study demonstrated the sustained efficacy & safety profile with no treatment-emergent resistance @144wks- >98% of treatment-naïve patients achieved and maintained undetectable viral load @4yrs.; viral suppression in 48wks. OLE period
  • In a subgroup analysis of patients with TDR- Biktarvy achieved comparably high levels of durable viral suppression @144 weeks among participants with and without TDR (98% vs 97%; as treated analysis)

 ­ Ref: Businesswire | Image: Gilead

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions